Preclinical Evaluation of Inducible Nitric Oxide Synthase Lipoplex Gene Therapy for Inhibition of Stent-Induced Vascular Neointimal Lesion Formation
Authors:
- 1 March 2003
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 14 (4) , 375-383
Abstract
Several reports have established the concept of nitric oxide synthase (NOS) gene transfer for inhibiting smooth muscle cell (SMC) proliferation after vascular injury. To minimize potential risks associated with viral gene transfer, we developed a liposome-based gene transfer approach employing inducible NOS (iNOS) overexpression for inhibition of stent-induced neointimal lesion formation. Therapeutic lipoplexes were transferred to femoral or coronary arteries of Goettingen minipigs, using the Infiltrator local drug delivery device. Efficiency of local iNOS lipoplex transfer was analyzed by iNOS-specific immunohistochemistry. NO-mediated inhibition of stent-induced neointimal lesion formation was analyzed by intravascular ultrasound (IVUS) and computerized morphometry. Gene transfer efficiency increased dose dependently to a maximum of 44.3 ± 4.2% iNOS-positive vessel area (dose, 2 μg of iNOS lipoplex). Proliferating cell nuclear antigen (PCNA) expression of medial SMCs (immunohistochemistry) was inhibited significantly by transfer of 2 μg of iNOS lipoplexes (111 ± 27 cells [iNOS] versus 481 ± 67 cells [control; PCNA-positive medial cells]). IVUS analysis demonstrated that local transfer of iNOS lipoplexes resulted in a significant reduction of femoral in-stent plaque area (control, 40.85 ± 6.37 mm2; iNOS, 24.69 ± 1.8 mm2; p = 0.03). Coronary in-stent lesion formation was reduced by about 45% as determined by histologic morphometry (control, 4.0 ± 0.29; iNOS, 2.2 ± 0.30; p < 0.01). In conclusion, this study demonstrates that local intramural delivery of iNOS lipoplexes can exert therapeutic effects in inhibiting stent-induced neointimal lesion formation. Together with the nonviral character of this gene therapy approach, these findings may have important impact on the transition of NOS-based gene therapy to clinical practice.Keywords
This publication has 22 references indexed in Scilit:
- Nitrotyrosine generation via inducible nitric oxide synthase in vascular wall in focal ischemia-reperfusionBrain Research, 2000
- A novel role for the cyclin-dependent kinase inhibitor p27Kip1 in angiotensin II–stimulated vascular smooth muscle cell hypertrophyJournal of Clinical Investigation, 1999
- Transfection of Inducible Nitric Oxide Synthase Gene Causes Apoptosis in Vascular Smooth Muscle CellsCirculation, 1998
- Induction of nitric oxide synthase in human vascular smooth muscle: interactions between proinflammatory cytokinesCardiovascular Research, 1998
- Human Endothelial Nitric Oxide Synthase Gene Transfer Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation After Balloon Injury in RatsCirculation, 1998
- Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary modelEuropean Heart Journal, 1998
- Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats.Journal of Clinical Investigation, 1996
- Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors.Journal of Clinical Investigation, 1995
- Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis modelJACC, 1994
- Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.Journal of Clinical Investigation, 1989